The U.S. Food and Drug Administration approved daraxonrasib, marketed as Rasonque by Revolution Medicines, as a targeted therapy for adults with advanced pancreatic cancer whose previous treatments failed. In a pivotal clinical trial of 500 patients, the daily pill nearly doubled overall survival to a median of 13.2 months compared to 6.7 months for chemotherapy.
Federal regulators granted expedited approval to the first-of-a-kind pill, which targets mutated proteins driving tumor growth in more than 90 percent of pancreatic cancer cases. For decades, this specific cancer driver was considered “undruggable”. The approval comes more than six months ahead of the target date set by regulators, providing a significant new option for patients facing one of the deadliest malignancies in the United States.
Clinical Trial Results and Survival Gains
The regulatory decision was supported by a company-funded phase 3 study that randomly assigned 500 patients whose metastatic cancer had stopped responding to prior treatments. Patients receiving daraxonrasib achieved a median overall survival of 13.2 months, while those receiving chemotherapy reached 6.7 months.
In addition to extending life, the therapy demonstrated a more favorable safety profile than traditional chemotherapy regimens. Reported side effects for the new drug included a skin rash, diarrhea, mouth sores, and other digestive issues.
Dr. Pashtoon Kasi of City of Hope Orange County, a California-based cancer center, stated that the treatment is not a cure but rather an additional option for those patients, adding that it represents the best option they have ever had.
Pancreatic cancer remains exceptionally difficult to treat because it is hard to detect before it starts spreading to other organs, and the American Cancer Society estimates about 67,000 new cases will be diagnosed in the U.S. this year, with more than 52,000 deaths. The five-year overall survival rate is 13 percent.
The biological barrier behind these grim statistics involves mutations in the RAS gene family, which regulates cell growth. In more than 90 percent of pancreatic cancers, KRAS mutations fuel tumor growth. Revolution Medicines designed daraxonrasib as an oral, multi-selective inhibitor that uses a molecular glue to bind with multiple KRAS subtypes and deactivate overactive proteins.
The treatment previously earned Breakthrough Therapy Designation and Orphan Drug Designation, and was selected for the FDA Commissioner’s National Priority Voucher pilot program.
Expanded Access Preceded Full Approval
Before the formal approval, public awareness surged when high-profile individuals shared their experiences. Former Nebraska Senator Ben Sasse described on television how he experienced reduced pain while taking the medication through expanded access pathways. At the same time, individual families and advocates campaigned to secure experimental doses for late-stage patients.
The FDA previously announced on May 1, 2026, that it was safe to proceed
with an Expanded Access Program for patients outside of clinical trials . Regional hospital networks, such as Intermountain Health, utilized those specialized programs to provide the treatment to eligible patients while awaiting full regulatory review.
Future Pipeline and Broader Cancer Implications
With daraxonrasib now commercially available under the brand name Rasonque, researchers are already looking toward its potential across other malignancies. Immuneering Corporation reported that its own oral MEK inhibitor, atebimetinib, is currently being evaluated in a global randomized Phase 3 trial known as MAPKeeper 301 for first-line metastatic pancreatic cancer patients.
Oncologists emphasize that daraxonrasib is not a cure, and surgery remains the only potential cure when the disease has not spread. However, medical specialists believe that validating the molecular glue approach against KRAS mutations opens doors for treating other tumor types, including non-small cell lung cancer and colorectal cancer.
